Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,022 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world status of multimodal treatment of Stage IIIA-N2 non-small cell lung cancer in Japan: Results from the SOLUTION study, a non-interventional, multicenter cohort study.
Horinouchi H, Murakami H, Harada H, Sobue T, Kato T, Atagi S, Kozuki T, Tokito T, Oizumi S, Seike M, Ohashi K, Mio T, Sone T, Iwao C, Iwane T, Koto R, Tsuboi M. Horinouchi H, et al. Among authors: tsuboi m. Lung Cancer. 2024 Nov 14;199:108027. doi: 10.1016/j.lungcan.2024.108027. Online ahead of print. Lung Cancer. 2024. PMID: 39708388 Free article.
Treatment patterns and clinical outcomes of resectable clinical stage III non-small cell lung cancer in a Japanese real-world setting: Surgery cohort analysis of the SOLUTION study.
Tsuboi M, Murakami H, Harada H, Sobue T, Kato T, Atagi S, Tokito T, Mio T, Adachi H, Kozuki T, Sone T, Seike M, Toyooka S, Kitagawa H, Koto R, Yamazaki S, Horinouchi H. Tsuboi M, et al. Thorac Cancer. 2024 Jul;15(20):1541-1552. doi: 10.1111/1759-7714.15305. Epub 2024 May 29. Thorac Cancer. 2024. PMID: 38812106 Free PMC article.
Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation.
Kitagawa S, Zenke Y, Taki T, Aokage K, Sakai T, Shibata Y, Izumi H, Nosaki K, Umemura S, Matsumoto S, Yoh K, Sakamoto N, Sakashita S, Kojima M, Tsuboi M, Goto K, Ishii G. Kitagawa S, et al. Among authors: tsuboi m. Lung Cancer. 2024 Feb;188:107453. doi: 10.1016/j.lungcan.2023.107453. Epub 2023 Dec 30. Lung Cancer. 2024. PMID: 38160515
Perioperative Nivolumab in Resectable Lung Cancer.
Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, Tanaka F, Taube JM, Cornelissen R, Havel L, Karaseva N, Kuzdzal J, Petruzelka LB, Wu L, Pujol JL, Ito H, Ciuleanu TE, de Oliveira Muniz Koch L, Janssens A, Alexandru A, Bohnet S, Moiseyenko FV, Gao Y, Watanabe Y, Coronado Erdmann C, Sathyanarayana P, Meadows-Shropshire S, Blum SI, Provencio Pulla M; CheckMate 77T Investigators. Cascone T, et al. N Engl J Med. 2024 May 16;390(19):1756-1769. doi: 10.1056/NEJMoa2311926. N Engl J Med. 2024. PMID: 38749033 Clinical Trial.
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.
Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S; KEYNOTE-671 Investigators. Spicer JD, et al. Among authors: tsuboi m. Lancet. 2024 Sep 28;404(10459):1240-1252. doi: 10.1016/S0140-6736(24)01756-2. Epub 2024 Sep 14. Lancet. 2024. PMID: 39288781 Clinical Trial.
Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.
Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, Tsuboi M, Yokota S, Nakagawa K, Suga M; Japan Thoracic Radiology Group; Jiang H, Itoh Y, Armour A, Watkins C, Higenbottam T, Nyberg F. Kudoh S, et al. Among authors: tsuboi m. Am J Respir Crit Care Med. 2008 Jun 15;177(12):1348-57. doi: 10.1164/rccm.200710-1501OC. Epub 2008 Mar 12. Am J Respir Crit Care Med. 2008. PMID: 18337594
Effect of tumor size on prognosis in patients treated with radical radiotherapy or chemoradiotherapy for non-small cell lung cancer. An analysis of the staging project database of the International Association for the Study of Lung Cancer.
Ball D, Mitchell A, Giroux D, Rami-Porta R; IASLC Staging Committee and Participating Institutions. Ball D, et al. J Thorac Oncol. 2013 Mar;8(3):315-21. doi: 10.1097/JTO.0b013e31827dc74d. J Thorac Oncol. 2013. PMID: 23334092 Free article.
Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer.
Spicer JD, Cascone T, Wynes MW, Ahn MJ, Dacic S, Felip E, Forde PM, Higgins KA, Kris MG, Mitsudomi T, Provencio M, Senan S, Solomon BJ, Tsao MS, Tsuboi M, Wakelee HA, Wu YL, Chih-Hsin Yang J, Zhou C, Harpole DH, Kelly KL. Spicer JD, et al. Among authors: tsuboi m. J Thorac Oncol. 2024 Oct;19(10):1373-1414. doi: 10.1016/j.jtho.2024.06.010. Epub 2024 Jun 18. J Thorac Oncol. 2024. PMID: 38901648
NETosis in pulmonary pleomorphic carcinoma.
Oi H, Taki T, Kuroe T, Sakamoto N, Sakashita S, Kojima M, Sugiyama E, Umemura S, Sakai T, Izumi H, Zenke Y, Matsumoto S, Yoh K, Ishii M, Tsuboi M, Goto K, Ishii G. Oi H, et al. Among authors: tsuboi m. Cancer Sci. 2024 Nov 18. doi: 10.1111/cas.16332. Online ahead of print. Cancer Sci. 2024. PMID: 39555736 Free article.
Prognostic value of the international association for the study of lung cancer grading system and its association with the tumor microenvironment in stage I EGFR-muted lung adenocarcinoma.
Kubota S, Taki T, Miyoshi T, Tane K, Samejima J, Aokage K, Wakabayashi M, Nomura K, Nagamine M, Kojima M, Sakashita S, Sakamoto N, Tsuboi M, Ishii G. Kubota S, et al. Among authors: tsuboi m. Eur J Cancer. 2024 Aug;207:114184. doi: 10.1016/j.ejca.2024.114184. Epub 2024 Jun 24. Eur J Cancer. 2024. PMID: 38936102
1,022 results